Systematic review of clofazimine for the treatment of drug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 8, 2013, Pages 1001-1007

  Gopal, M ^a   Padayatchi, N ^b   Metcalfe, J Z ^c   O'Donnell, Max R ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clofazimine; MDR TB; Systematic review; Treatment outcome; XDR TB

Indexed keywords

CLOFAZIMINE;

ADVERSE OUTCOME; ANTIBIOTIC THERAPY; BANGLADESH; COHORT ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EXPERIMENTAL STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GASTROINTESTINAL SYMPTOM; HUMAN; ICHTHYOSIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN DISCOLORATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CLOFAZIMINE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84880454871     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0144     Document Type: Review

References (53)

1. Barry V C, Belton J G, Conalty M L, et al. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature 1957; 179: 1013-1015.
2. Barry V C, Buggle K, Byrne J, Conalty M L, Winder F. Absorption, distribution and retention of the riminocompounds in the experimental animal. Ir J Med Sci 1960; 416: 345-352.
3. Barry V C, Conalty M L. Anti-tuberculosis activity in the phenazine series. II. N3-substituted anilinoaposafranines (riminocompounds) and some derivatives. Am Rev Tuberc 1958; 78: 62-73.
4. Chang Y T. Chemotherapy of murine leprosy. IV. The effects of amithiozone (TB1/698), p-aminosalicylic acid (PAS), B 283 (a phenazine pigment), five antibiotics and three diphenylthiourea compounds on mouse leprosy. Int J Lepr 1955; 23: 167-180.
5. Moher D, Liberati A, Tetzlaff J, Altman D G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269, W64.
6. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
7. Harris R P, Helfand M, Woolf S H, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001; 20: 21-35. (Pubitemid 33732964)
8. Higgins J P, Altman D G, Gotzsche P C, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188. (Pubitemid 17189972)
10. Lijmer J G, Bossuyt P M, Heisterkamp S H. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med 2002; 21: 1525-1537. (Pubitemid 34746061)
11. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634. (Pubitemid 27387172)
12. Morrison N E, Marley G M. Clofazimine binding studies with deoxyribonucleic acid. Int J Lepr Other Mycobact Dis 1976; 44: 475-481. (Pubitemid 8073770)
13. Arbiser J L, Moschella S L. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol 1995; 32: 241-247.
14. Yano T, Kassovska-Bratinova S, Teh J S, et al. Reduction of clofazimine by mycobacterial type 2 NADH: quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 2011; 286: 10276-10287.
15. Oliva B, O'Neill A J, Miller K, Stubbings W, Chopra I. Antistaphylococcal activity and mode of action of clofazimine. J Antimicrob Chemother 2004; 53: 435-440. (Pubitemid 38380239)
16. Grant S S, Kaufmann B B, Chand N S, Haseley N, Hung D T. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc Natl Acad Sci USA 2012; 109: 12147-12152.
17. Reddy V M, O'Sullivan J F, Gangadharam P R. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother 1999; 43: 615-623. (Pubitemid 29231686)
18. Parak R B, Wadee A A. The synergistic effects of gamma interferon and clofazimine on phagocyte function: restoration of inhibition due to a 25 kilodalton fraction from Mycobacterium tuberculosis. Biotherapy 1991; 3: 265-272.
19. Wadee A A, Anderson R, Rabson A R. Clofazimine reverses the inhibitory effect of Mycobacterium tuberculosis derived factors on phagocyte intracellular killing mechanisms. J Antimicrob Chemother 1988; 21: 65-74.
20. Tasneen R, Li S Y, Peloquin C A, et al. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 2011; 55: 5485-5492.
21. Lu Y, Wang B, Zhao W J, et al. [A study on the activity of clofazimine with antituberculous drugs against Mycobacterium tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi 2010; 33: 675-678. [Chinese]
22. Holdiness M R. Clinical pharmacokinetics of clofazimine. A review. Clin Pharmacokinet 1989; 16: 74-85. (Pubitemid 19074276)
23. Nix D E, Adam R D, Auclair B, Krueger T S, Godo P G, Peloquin C A. Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis (Edinb) 2004; 84: 365-373. (Pubitemid 39451903)
24. Adams L B, Sinha I, Franzblau S G, Krahenbuhl J L, Mehta R T. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob Agents Chemother 1999; 43: 1638-1643. (Pubitemid 29331240)
25. Dooley K E, Obuku E A, Durakovic N, Belitsky V, Mitnick C, Nuermberger E L. World Health Organization Group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis 2012; 30 Aug. [Epub ahead of print]
26. Williams K, Minkowski A, Amoabeng O, et al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012; 56: 3114-3120.
27. Steenken W Jr, Montalbine V, Smith M M. Antituberculous activity of rimino compound of the phenazine series. Am Rev Respir Dis 1960; 81: 764-767.
28. Friedman L N. Tuberculosis: current concepts and treatment. Boca Raton, FL, USA: CRC Press, 1994.
29. Mauch H, Reichert B, Ruf B, Brehmer W. [Resistance testing of M. avium-intracellulare and M. tuberculosis of AIDS patients with new drugs and drug combinations]. Pneumologie 1990; 44 (Suppl 1): 504-506. [German]
30. van Ingen J, Simons S, de Zwaan R, et al. Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010; 48: 2749-2753.
31. Rastogi N, Ross B C, Dwyer B, et al. Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 1992; 11: 901-907. (Pubitemid 23011897)
32. Satana D, Coban A Y, Uzun M. Testing susceptibility of multidrug- resistant Mycobacterium tuberculosis to second-line drugs by use of blood agar. J Clin Microbiol 2010; 48: 4291-4293.
33. Balabanova Y, Ruddy M, Hubb J, et al. Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy. Eur J Clin Microbiol Infect Dis 2005; 24: 136-139. (Pubitemid 40487382)
34. Schön T, Juréen P, Chryssanthou E, et al. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2011; 15: 502-509.
35. Furin J J, Mitnick C D, Shin S S, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648-655. (Pubitemid 32652155)
36. Moore V J. A review of side-effects experienced by patients taking clofazimine. Lepr Rev 1983; 54: 327-335. (Pubitemid 14152051)
37. Geerligs W A, van Altena R, de Lange W C M, van Soolingen D, van der Werf T S. Multidrug-resistant tuberculosis: longterm treatment outcome in the Netherlands. Int J Tuberc Lung Dis 2000; 4: 758-764. (Pubitemid 30650034)
38. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128. (Pubitemid 36056718)
39. Senaratne W V. Outcome of treatment of multidrug-resistant tuberculosis. Ceylon Med J 2004; 49: 86-87.
40. Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005; 56: 180-185.
41. Mitnick C D, Shin S S, Seung K J, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-574.
42. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom W N. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008; 134: 187-192. (Pubitemid 352008783)
43. Van Deun A, Maug A K, Salim M A, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
44. Xu H B, Jiang R H, Xiao H P. Clofazimine in the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect 2011; 18: 1104-1110.
45. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C R Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532. (Pubitemid 23053828)
46. World Health Organization. WHO Expert Committee on Leprosy. Seventh report. Technical Report Series 874. Geneva, Switzerland: WHO, 1998.
47. Mukherjee J S, Rich M L, Socci A R, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474-481. (Pubitemid 38210067)
48. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
49. Jacobson K R, Tierney D B, Jeon C Y, Mitnick C D, Murray M B. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
50. Reddy V M, Nadadhur G, Daneluzzi D, O'Sullivan J F, Gangadharam P R. Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrob Agents Chemother 1996; 40: 633-636. (Pubitemid 26075433)
51. Jagannath C, Reddy M V, Kailasam S, O'Sullivan J F, Gangadharam P R. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis: in vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med 1995; 151: 1083-1086.
52. Caminero J A, Sotgiu G, Zumla A, Migliori G B. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-629.
53. Peloquin C A. Shortages of antimycobacterial drugs. N Engl J Med 1992; 326: 714.